Here is a brief preview of this blast: Regeneron has posted a Ph1 FIH SAD/MAD study investigating the safety, tolerability, and PK of REGN20566 in non-T2DM adult participants with overweight or obesity (view CT.gov record). This is believed to be the first public disclosure of the asset, with its MOA, ROA, and dosing frequency unknown. Below, FENIX provides highlights and insights from the study.
About The Author
Matthew Maryniak
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.